Artificial intelligence giant Anthropic is pushing deeper into drug discovery, building its own molecular biology lab and investing in research that could eventually produce drug candidates, according to the company's blockbuster IPO filing.
The maker of the Claude AI platform laid out its growing ambitions in life sciences in a much-anticipated S-1 filed with the U.S. Securities and Exchange Commission on Monday, while acknowledging that its expansion into drug development brings scientific, regulatory and operational challenges that extend well beyond its traditional software business.
In the run-up to its initial public offering, Anthropic outlined its vision for what it calls “Powerful AI,” a highly capable form of artificial intelligence that the company believes could become widely available within a few years. Anthropic envisions AI systems that could match or exceed the capabilities of top human experts across scientific disciplines, perform complex tasks autonomously and operate laboratory equipment and robotic systems.
“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is extraordinary,” Anthropic said in the filing, pointing to the possibility of “accelerating drug discovery, disease detection, and the delivery of personalized therapy” as one of the technology's potential benefits.
Anthropic is preparing to go public under the Nasdaq ticker symbol “ANT,” with an offering that could raise more than $100 billion and push its valuation toward $2 trillion, according to an August report from The New York Times. The S-1 does not yet specify an offering price or the number of shares to be sold.
Meanwhile, Anthropic has already made inroads into the drug development industry through partnerships with pharma giants such as Novo Nordisk and Bristol Myers Squibb. It also brought Novartis CEO Vas Narasimhan onto its board of directors in April.
Anthropic's push into the sector also includes its Claude for Life Sciences platform, designed to support scientists and researchers across drug development, from early discovery and preclinical research to clinical trial operations and regulatory submissions.
According to the filing, the platform integrates with electronic laboratory notebooks, scientific databases and other research tools while providing specialized capabilities in organic chemistry, structural biology, laboratory protocols and bioinformatics.
Beyond its partnerships with drugmakers, Anthropic is building its own life sciences research capabilities, hiring industry specialists, establishing a molecular biology laboratory and deploying Claude in drug discovery and development through its own researchers.
Anthropic is also looking to bring AI into physical laboratory operations. The company said its Model Hardware Standard enables AI agents to operate laboratory and manufacturing equipment, including microscopes, liquid handlers and commercially available robotic arms.
The company has further expanded its internal research capabilities through its April acquisition of Coefficient Bio, a computational biology startup, in a deal previously reported to be worth $400 million. The S-1 disclosed that the transaction involved 15.4 million Anthropic shares, with a portion of the consideration tied to continued employee service.
Together, those efforts suggest Anthropic is positioning itself to participate more directly in scientific discovery rather than simply supplying technology to researchers.
Eric Kauderer-Abrams, Anthropic's head of biology and life sciences, told Fierce Healthcare in January that healthcare and life sciences represent one of the company's biggest strategic bets.
That opportunity comes with a new set of risks, however, and Anthropic's IPO filing offers a particularly candid assessment of the challenges it could encounter as its research ambitions expand.
The company acknowledged that its life sciences research program requires activities outside its historical experience as a software and AI research organization, including handling biological and chemical materials, operating laboratory equipment and complying with biosafety and environmental requirements.
Those activities could expose Anthropic to new liabilities, including workplace injuries and environmental contamination, while potentially subjecting its operations to preclinical and clinical research regulations.
Anthropic specifically cautioned that any drug candidates or discoveries emerging from its research would face the “lengthy, costly, and uncertain development and regulatory pathways characteristic of the life sciences industry” and might never generate revenue.
The company also highlighted the potential consequences of using AI in sensitive scientific and healthcare settings, including errors, inaccurate results and hallucinations that could contribute to patient harm or compromised research.
“We may be unable to fully understand or explain why our models produce particular outputs or behave in particular ways, which could limit our ability to predict or prevent failures, provide explanations to customers or regulators, or satisfy emerging regulatory, transparency, and explainability requirements,” the company said in the S-1.
As Anthropic expands its healthcare and life sciences offerings, it could also face oversight under laws governing drugs, biologics, medical devices and protected health information, including regulations administered by the FDA and comparable international agencies.
Regulators could require the company to obtain additional authorizations, modify its products or restrict certain applications, the filing warned.
Anthropic has already faced regulatory and political headwinds. In March, the Department of Health and Human Services barred employees from using Claude as President Donald Trump sought to blacklist the company's technology across the federal government. Competing products from OpenAI and Google remained available to federal employees.
The dispute also raised questions about AI adoption at the FDA, which initially relied on Claude for its Elsa platform, designed to help accelerate aspects of the drug review process. The agency has since transitioned to Google's Gemini as its primary AI model.
Despite those challenges, Anthropic is betting on life sciences as a significant growth opportunity. The company cited expectations that global pharmaceutical spending would exceed $2 trillion in 2026 as it outlined plans to expand into industries where AI could accelerate new discoveries.
Its IPO filing makes clear that the company sees a role for itself on both sides of that equation, supplying AI technology to drugmakers while building the research infrastructure to pursue scientific discoveries of its own.